Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Incubation time of Mycobacterium tuberculosis complex sputum cultures in BACTEC MGIT 960: 4weeks of negative culture is enough for physicians to consider alternative diagnoses.

Ogwang S, Mubiri P, Bark CM, Joloba ML, Boom WH, Johnson JL.

Diagn Microbiol Infect Dis. 2015 Jul 9. pii: S0732-8893(15)00228-X. doi: 10.1016/j.diagmicrobio.2015.07.002. [Epub ahead of print]

PMID:
26239846
2.

Predictors for MTB Culture-Positivity among HIV-Infected Smear-Negative Presumptive Tuberculosis Patients in Uganda: Application of New Tuberculosis Diagnostic Technology.

Nakiyingi L, Nonyane BA, Ssengooba W, Kirenga BJ, Nakanjako D, Lubega G, Byakika-Kibwika P, Joloba ML, Ellner JJ, Dorman SE, Mayanja-Kizza H, Manabe YC.

PLoS One. 2015 Jul 29;10(7):e0133756. doi: 10.1371/journal.pone.0133756. eCollection 2015.

3.

High Genotypic Discordance of Concurrent Mycobacterium tuberculosis Isolates from Sputum and Blood of HIV-Infected Individuals.

Ssengooba W, Cobelens FG, Nakiyingi L, Mboowa G, Armstrong DT, Manabe YC, Joloba ML, de Jong BC.

PLoS One. 2015 Jul 15;10(7):e0132581. doi: 10.1371/journal.pone.0132581. eCollection 2015.

4.

Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda.

Nakiyingi L, Ssengooba W, Nakanjako D, Armstrong D, Holshouser M, Kirenga BJ, Shah M, Mayanja-Kizza H, Joloba ML, Ellner JJ, Dorman SE, Manabe YC.

BMC Infect Dis. 2015 Feb 15;15:62. doi: 10.1186/s12879-015-0812-4.

5.

Pertussis prevalence and its determinants among children with persistent cough in urban Uganda.

Kayina V, Kyobe S, Katabazi FA, Kigozi E, Okee M, Odongkara B, Babikako HM, Whalen CC, Joloba ML, Musoke PM, Mupere E.

PLoS One. 2015 Apr 15;10(4):e0123240. doi: 10.1371/journal.pone.0123240. eCollection 2015.

6.

Optimizing tuberculosis case detection through a novel diagnostic device placement model: the case of Uganda.

Pho MT, Deo S, Palamountain KM, Joloba ML, Bajunirwe F, Katamba A.

PLoS One. 2015 Apr 1;10(4):e0122574. doi: 10.1371/journal.pone.0122574. eCollection 2015.

7.

Improving the sensitivity of the Xpert MTB/RIF assay on sputum pellets by decreasing the amount of added sample reagent: a laboratory and clinical evaluation.

Dharan NJ, Amisano D, Mboowa G, Ssengooba W, Blakemore R, Kubiak RW, Armstrong DT, Jones M, Manabe YC, Joloba ML, Ellner JJ, Dorman SE, Alland D.

J Clin Microbiol. 2015 Apr;53(4):1258-63. doi: 10.1128/JCM.03619-14. Epub 2015 Feb 4.

PMID:
25653410
8.

Comparison of MGIT and Myco/F lytic liquid-based blood culture systems for recovery of Mycobacterium tuberculosis from pleural fluid.

Harausz E, Lusiba JK, Nsereko M, Johnson JL, Toossi Z, Ogwang S, Boom WH, Joloba ML; Tuberculosis Research Unit (TBRU).

J Clin Microbiol. 2015 Apr;53(4):1391-4. doi: 10.1128/JCM.02742-14. Epub 2015 Feb 4.

PMID:
25653400
9.

Feasibility of establishing a biosafety level 3 tuberculosis culture laboratory of acceptable quality standards in a resource-limited setting: an experience from Uganda.

Ssengooba W, Gelderbloem SJ, Mboowa G, Wajja A, Namaganda C, Musoke P, Mayanja-Kizza H, Joloba ML.

Health Res Policy Syst. 2015 Jan 15;13:4. doi: 10.1186/1478-4505-13-4.

10.

The Mycobacterium tuberculosis Uganda II family and resistance to first-line anti-tuberculosis drugs in Uganda.

Ezati N, Lukoye D, Wampande EM, Musisi K, Kasule GW, Cobelens FG, Kateete DP, Joloba ML.

BMC Infect Dis. 2014 Dec 19;14:703. doi: 10.1186/s12879-014-0703-0.

11.

Polymorphisms in TICAM2 and IL1B are associated with TB.

Hall NB, Igo RP Jr, Malone LL, Truitt B, Schnell A, Tao L, Okware B, Nsereko M, Chervenak K, Lancioni C, Hawn TR, Mayanja-Kizza H, Joloba ML, Boom WH, Stein CM; Tuberculosis Research Unit.

Genes Immun. 2015 Mar;16(2):127-33. doi: 10.1038/gene.2014.77. Epub 2014 Dec 18.

PMID:
25521228
12.

Clinical utility of a novel molecular assay in various combination strategies with existing methods for diagnosis of HIV-related tuberculosis in Uganda.

Ssengooba W, Nakiyingi L, Armstrong DT, Cobelens FG, Alland D, Manabe YC, Dorman SE, Ellner JJ, Joloba ML.

PLoS One. 2014 Sep 15;9(9):e107595. doi: 10.1371/journal.pone.0107595. eCollection 2014.

13.

Evaluation of Cepheid's Xpert MTB/Rif test on pleural fluid in the diagnosis of pleural tuberculosis in a high prevalence HIV/TB setting.

Lusiba JK, Nakiyingi L, Kirenga BJ, Kiragga A, Lukande R, Nsereko M, Ssengooba W, Katamba A, Worodria W, Joloba ML, Mayanja-Kizza H.

PLoS One. 2014 Jul 22;9(7):e102702. doi: 10.1371/journal.pone.0102702. eCollection 2014.

14.

Clinical and epidemiological characteristics of individuals resistant to M. tuberculosis infection in a longitudinal TB household contact study in Kampala, Uganda.

Ma N, Zalwango S, Malone LL, Nsereko M, Wampande EM, Thiel BA, Okware B, Igo RP Jr, Joloba ML, Mupere E, Mayanja-Kizza H, Boom WH, Stein CM; Tuberculosis Research Unit (TBRU).

BMC Infect Dis. 2014 Jun 27;14:352. doi: 10.1186/1471-2334-14-352.

15.

The T2 Mycobacterium tuberculosis genotype, predominant in Kampala, Uganda, shows negative correlation with antituberculosis drug resistance.

Lukoye D, Katabazi FA, Musisi K, Kateete DP, Asiimwe BB, Okee M, Joloba ML, Cobelens FG.

Antimicrob Agents Chemother. 2014 Jul;58(7):3853-9. doi: 10.1128/AAC.02338-13. Epub 2014 Apr 28.

16.

What is the most reliable solid culture medium for tuberculosis treatment trials?

Joloba ML, Johnson JL, Feng PJ, Bozeman L, Goldberg SV, Morgan K, Gitta P, Boom HW, Heilig CM, Mayanja-Kizza H, Eisenach KD.

Tuberculosis (Edinb). 2014 May;94(3):311-6. doi: 10.1016/j.tube.2014.03.002. Epub 2014 Mar 19.

PMID:
24698569
17.

Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults.

Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, Armstrong DT, Zemanay W, Sikhondze W, Mbabazi O, Nonyane BA, Shah M, Joloba ML, Alland D, Ellner JJ, Dorman SE.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):270-9. doi: 10.1097/QAI.0000000000000151.

18.

How we determined the most reliable solid medium for studying treatment of tuberculosis.

Heilig CM, Feng PJ, Joloba ML, Johnson JL, Morgan K, Gitta P, Boom WH, Mayanja-Kizza H, Eisenach KD, Bozeman L, Goldberg SV.

Tuberculosis (Edinb). 2014 May;94(3):317-22. doi: 10.1016/j.tube.2014.02.006. Epub 2014 Mar 4.

19.

A metabolic biosignature of early response to anti-tuberculosis treatment.

Mahapatra S, Hess AM, Johnson JL, Eisenach KD, DeGroote MA, Gitta P, Joloba ML, Kaplan G, Walzl G, Boom WH, Belisle JT.

BMC Infect Dis. 2014 Jan 31;14:53. doi: 10.1186/1471-2334-14-53.

20.

Differential prevalence of transporter polymorphisms in symptomatic and asymptomatic falciparum malaria infections in Uganda.

Tukwasibwe S, Mugenyi L, Mbogo GW, Nankoberanyi S, Maiteki-Sebuguzi C, Joloba ML, Nsobya SL, Staedke SG, Rosenthal PJ.

J Infect Dis. 2014 Jul 1;210(1):154-7. Epub 2014 Jan 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk